Inhibitor-sensitive AmpC β-lactamase variant produced by an Escherichia coli clinical isolate resistant to oxyiminocephalosporins and cephamycins

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 7, 2004, Pages 2652-2658

  Doi, Yohei ^a   Wachino, Jun Ichi ^a   Ishiguro, Masaji ^b   Kurokawa, Hiroshi ^a   Yamane, Kunikazu ^a   Shibata, Naohiro ^a   Shibayama, Keigo ^a   Yokoyama, Keiko ^a   Kato, Haru ^a   Yagi, Tetsuya ^a   Arakawa, Yoshichika ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b SUNTORY INSTITUTE FOR BIOORGANIC RESEARCH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ASPARTIC ACID; AZTREONAM; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CEFALORIDINE; CEFEPIME; CEFMETAZOLE; CEFMINOX; CEFOTAXIME; CEFOXITIN; CEFPIROME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CEPHAMYCIN DERIVATIVE; CHLORAMPHENICOL; CLAVULANIC ACID; ENZYME VARIANT; GLYCINE; IMIPENEM; LATAMOXEF; OXYIMINOCEPHALOSPORIN DERIVATIVE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SERINE; SULBACTAM; TAZOBACTAM; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CHROMOSOME; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BINDING SITE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; ENZYME ANALYSIS; ENZYME ASSAY; ENZYME INHIBITION; ENZYME STRUCTURE; ENZYME SUBSTRATE COMPLEX; ENZYME SYNTHESIS; ESCHERICHIA COLI; GENE DELETION; GENE INSERTION; GENE LOCATION; JAPAN; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR CLONING; MOLECULAR MODEL; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY;

AMINO ACID SEQUENCE; BACTERIAL PROTEINS; BETA-LACTAMASES; CEFTAZIDIME; CEPHALOSPORIN RESISTANCE; CEPHALOSPORINS; CEPHAMYCINS; CLONING, MOLECULAR; CULTURE MEDIA; ENZYME INHIBITORS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; GENE DELETION; GENE TRANSFER, HORIZONTAL; ISOELECTRIC FOCUSING; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PLASMIDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SUBSTRATE SPECIFICITY;

EID: 3042677882     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.7.2652-2658.2004     Document Type: Article

References (28)

1. Babini, G. S., F. Danel, S. D. Munro, P. A. Micklesen, and D. M. Livermore. 1998. Unusual tazobactam-sensitive AmpC β-lactamase from two Escherichia coli isolates. J. Antimicrob. Chemother. 41:115-118.
2. Barnaud, G., R. Labia, L. Raskine, M. J. Sanson-Le Pors, A. Philippon, and G. Arlet. 2001. Extension of resistance to cefepime and cefpirome associated to a six amino acid deletion in the H-10 helix of the cephalosporinase of an Enterobacter cloacae clinical isolate. FEMS Microbiol. Lett. 195:185-190.
3. Bush, K. 2001. New β-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. Clin. Infect. Dis. 32:1085-1089.
4. Bush, K., C. Macalintal, B. A. Rasmussen, V. J. Lee, and Y. Yang. 1993. Kinetic interactions of tazobactam with β-lactamases from all major structural classes. Antimicrob. Agents Chemother. 37:851-858.
5. Caroff, N., E. Espaze, I. Berard, H. Richet, and A. Reynaud. 1999. Mutations in the ampC promoter of Escherichia coli isolates resistant to oxyiminocephalosporins without extended spectrum β-lactamase production. FEMS Microbiol. Lett. 173:459-465.
6. Crichlow, G. V., A. P. Kuzin, M. Nukaga, K. Mayama, T. Sawai, and J. R. Knox. 1999. Structure of the extended-spectrum class C β-lactamase of Enterobacter cloacae GC1, a natural mutant with a tandem tripeptide insertion. Biochemistry 38:10256-10261.
7. Denome, S. A., P. K. Elf, T. A. Henderson, D. E. Nelson, and K. D. Young. 1999. Escherichia coli mutants lacking all possible combinations of eight penicillin binding proteins: viability, characteristics, and implications for peptidoglycan synthesis. J. Bacteriol. 181:3981-3993.
8. Edlund, T., T. Grundstrom, and S. Normark. 1979. Isolation and characterization of DNA repetitions carrying the chromosomal β-lactamase gene of Escherichia coli K-12. Mol. Gen. Genet. 173:115-125.
9. Hashimoto-Gotoh, T., T. Mizuno, Y. Ogasahara, and M. Nakagawa. 1995. An oligodeoxyribonucleotide-directed dual Amber method for site-directed mutagenesis. Gene 152:271-275.
10. Jaurin, B., and T. Grundstrom. 1981. ampC cephalosporinase of Escherichia coli K-12 has a different evolutionary origin from that of β-lactamases of the penicillinase type. Proc. Natl. Acad. Sci. USA 78:4897-4901.
11. Jaurin, B., T. Grundstrom, T. Edlund, and S. Normark. 1981. The E. coli β-lactamase attenuator mediates growth rate-dependent regulation. Nature 290:221-225.
12. Kato-Toma, Y., T. Iwashita, K. Matsuda, Y. Oyama, and M. Ishiguro. 2003. pKa measurements from nuclear magnetic resonance of tyrosine-150 in class C β-lactamase. Biochem. J. 371:175-181.
13. Livermore, D. M. 1995. β-Lactamases in laboratory and clinical resistance. Clin. Microbiol. Rev. 8:557-584.
14. Livermore, D. M. 1993. Determinants of the activity of β-lactamase inhibitor combinations. J. Antimicrob. Chemother. 31(Suppl. A):9-21.
15. Livermore, D. M., and D. F. Brown. 2001. Detection of β-lactamase-mediated resistance. J. Antimicrob. Chemother. 48(Suppl. 1):59-64.
16. Lobkovsky, E., P. C. Moews, H. Liu, H. Zhao, J. M. Frere, and J. R. Knox. 1993. Evolution of an enzyme activity: crystallographic structure at 2-Å resolution of cephalosporinase from the ampC gene of Enterobacter cloacae P99 and comparison with a class A penicillinase. Proc. Natl. Acad. Sci. USA 90:11257-11261.
17. Medeiros, A. A. 1997. Evolution and dissemination of β-lactamases accelerated by generations of β-lactam antibiotics. Clin. Infect. Dis. 24(Suppl. 1):S19-S45.
18. National Committee for Clinical Laboratory Standards. 2000. Methods for disk antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A5. National Committee for Clinical Laboratory Standards, Wayne Pa.
19. Nelson, E. C., and B. G. Elisha. 1999. Molecular basis of AmpC hyperproduction in clinical isolates of Escherichia coli. Antimicrob. Agents Chemother. 43:957-959.
20. Nukaga, M., S. Haruta, K. Tanimoto, K. Kogure, K. Taniguchi, M. Tamaki, and T. Sawai. 1995. Molecular evolution of a class C β-lactamase extending its substrate specificity. J. Biol. Chem. 270:5729-5735.
21. Olsson, O., S. Bergstrom, F. P. Lindberg, and S. Normark. 1983. ampC β-lactamase hyperproduction in Escherichia coli: natural ampicillin resistance generated by horizontal chromosomal DNA transfer from Shigella. Proc. Natl. Acad. Sci. USA 80:7556-7560.
22. Olsson, O., S. Bergstrom, and S. Normark. 1982. Identification of a novel ampC β-lactamase promoter in a clinical isolate of Escherichia coli. EMBO J. 1:1411-1416.
23. Powers, R. A., E. Caselli, P. J. Focia, F. Prati, and B. K. Shoichet. 2001. Structures of ceftazidime and its transition-state analogue in complex with AmpC β-lactamase: implications for resistance mutations and inhibitor design. Biochemistry 40:9207-9214.
24. Sambrook, J., E. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
25. Usher, K. C., L. C. Blaszczak, G. S. Weston, B. K. Shoichet, and S. J. Remington. 1998. Three-dimensional structure of AmpC β-lactamase from Escherichia coli bound to a transition-state analogue: possible implications for the oxyanion hypothesis and for inhibitor design. Biochemistry 37:16082-16092.
26. Wong-Beringer, A., J. Hindler, M. Loeloff, A. M. Queenan, N. Lee, D. A. Pegues, J. P. Quinn, and K. Bush. 2002. Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime. Clin. Infect. Dis. 34:135-146.
27. Yagi, T., H. Kurokawa, N. Shibata, K. Shibayama, and Y. Arakawa. 2000. A preliminary survey of extended-spectrum β-lactamases (ESBLs) in clinical isolates of Klebsiella pneumoniae and Escherichia coli in Japan. FEMS Microbiol. Lett. 184:53-56.
28. Yang, Y., B. A. Rasmussen, and D. M. Shlaes. 1999. Class A β-lactamases-enzyme-inhibitor interactions and resistance. Pharmacol. Ther. 83:141-151.